PT - JOURNAL ARTICLE AU - Pung, Rachael AU - Kong, Xin Peng AU - Cui, Lin AU - Chae, Sae-Rom AU - Chen, Mark I-Cheng AU - Lee, Vernon J. AU - Marc Ho, Zheng Jie TI - Severity of SARS-CoV-2 Omicron XBB subvariants in Singapore AID - 10.1101/2023.05.04.23289510 DP - 2023 Jan 01 TA - medRxiv PG - 2023.05.04.23289510 4099 - http://medrxiv.org/content/early/2023/05/10/2023.05.04.23289510.short 4100 - http://medrxiv.org/content/early/2023/05/10/2023.05.04.23289510.full AB - Several XBB subvariants such as XBB.1.5, XBB.1.9, XBB.1.16 and XBB.2.3 co-circulate in Singapore. Despite the different viral properties of XBB.1.16 as compared to other XBB subvariants, comparison on their severity is limited. In this study, we investigate the outcomes of hospitalisation and severe COVID-19 infection in individuals infected with different XBB subvariants, adjusted for potential confounders such as age and vaccination history. Overall, our preliminary analysis showed no difference in the severity of different XBB variants.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the London School of Hygiene & Tropical Medicine Observational Research Ethics Committee (ref. 25727). All data and analysis were collected and performed in line with the Infectious Diseases Act in Singapore which permits the collection and publication of surveillance data.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present work are contained in the manuscript